Revance Therapeutics Stock (NASDAQ: RVNC)

Revance Therapeutics Stock (NASDAQ:RVNC), Trade Ideas

Revance Therapeutics

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABSI

BILI

LYEL

MRNA

MRVI

NRIX

RVNC

TSHA

TSLA

XPEV

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.

Shares of  BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.

BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday

Pre-Market Outlook

COIN

GRPH

HSAI

MARA

MSTR

U.S. stock futures were lower this morning, with the Dow futures falling by around 100 points on Monday.

Shares of  GDS Holdings Limited  (NASDAQ: GDS) shares rose sharply in today’s pre-market trading.

GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday&#39;s Pre-Market Session

AADI

AIMD

AKRO

APVO

ASTR

BBAI

BCDA

BIVI

BTDR

BYND

CMCL

CRDF

CRML

DWAC

ETNB

FUFU

HSDT

IFBD

JAGX

JOAN

LIFW

MGEE

MINM

NKTR

NYCB

OCEA

PHUN

PLTK

QNRX

RELI

RENB

RNLX

SABR

SAVE

SBFM

SMCI

TRNR

VANI

ZJYL

Shares of  Bitdeer Technologies Group  (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Revance Therapeutics, Inc. - Common Stock

Revance Therapeutics Inc

– Two presentations highlighting data on DAXXIFY&#xAE; for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY's formulation on clinical performance
Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>), today announced two poster presentations on DAXXIFY&#xAE; for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
In the ASPEN-1 and ASPEN-OLS (open label study), a new analysis found that among patients that requested early retreatment with DAXXIFY&#xAE;, roughly 50% of peak efficacy remained at the time of their request. In the ASPEN-OLS 52-week long-term follow-up study, approximately 60% of retreatments were at 16 weeks or later. These findings suggest that the long-acting symptom control with DAXXIFY&#xAE; allows physicians the flexibility to customize treatment intervals for each patient, without being limited by the FDA and payer-defined minimum treatment interval of 12 weeks (as is the case with conventional neurotoxins). Additionally, the studies show that adverse event rates remained low across all retreatment scenarios.
"While it may not be surprising that many patients prefer to be retreated as their symptoms first re-emerge rather than waiting to return to baseline, we believe that the duration of DAXXIFY offers the potential for physicians to tailor doses and retreatment intervals to the needs of individual patients, in order to provide sustained symptom control and reduce the symptom rollercoaster experienced by a vast number of those suffering with cervical dystonia," said David. A. Hollander, MD, MBA, Chief Medical Officer and Global Therapeutics Franchise Lead.
A second poster, by Dr. Han Lee and colleagues, examines DAXXIFY's novel formulation and the role of Revance's custom-engineered peptide (RTP004), in clinical performance. The data shows that the benefits of RTP004 include increased binding of neurotoxin to cell membranes to allow more toxin to enter the neuron, enhanced SNAP-25 cleavage in neurons in a dose-dependent manner, and localization in the injected muscle. By increasing bioavailability, DAXXIFY's formulation allows for a lower amount of core neurotoxin to be administered while maintaining long lasting benefit, which may contribute to the strong safety and differentiated performance profile.
Poster Details:
<ul>
<li>Title: Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical Dystonia: Potential for a New Treatment Paradigm With DaxibotulinumtoxinA</li>
<li>Authors and Affiliation: Aaron Ellenbogen, Robert A. Hauser, Atul Patel, Peter McAllister, Domenico Vitarella, Todd Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander, Michigan Institute for Neurological Disorders, Farmington Hills, MI, USA; University of South Florida, Tampa, FL, USA; Kansas City Bone &amp; Joint Clinic, Overland Park, KS, USA; New England Institute for Neurology and Headache, Stamford, CT, USA; Revance Therapeutics, Inc., Nashville, TN, USA</li>
<li>Title: Influence of Novel Formulation in DaxibotulinumtoxinA on Efficacy for Treatment of Cervical Dystonia
<ul>
<li>Authors and Affiliation: Han Lee, André F. Batista, Conor J. Gallagher, The Permanente Medical Group, San Leandro, CA, USA; Revance Therapeutics, Inc., Nashville, TN, USA</li>
</ul>
</li>
</ul>

Biotech

General

Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
Shares of BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) rose <a href="https://www.benzinga.com/markets/equities/24/04/38159493/why-is-blackberry-stock-rising-today">sharply during Tuesday&rsquo;s session</a>.
The company announced a collaboration with Advanced Micro Devices, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amd#NASDAQ">AMD</a>), designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter, as well as repeatable determinism.
BlackBerry shares jumped 9% to $3.1340 on Tuesday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) jumped 19% to $16.42. Nurix Therapeutics announced extension of strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) shares climbed 14% to $3.0650 after Piper Sandler initiated coverage on the stock with an Overweight rating and a price target of $9.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) gained 10.5% to $2.42.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) climbed 10.3% to $3.00.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) climbed 8.7% to $8.02.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) gained 8.6% to $4.8350.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) gained 8.3% to $113.81.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) shares rose 7.7% to $4.7050. NIO filed its 2023 annual report on Form 20-F.</li>
<li>Absci Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/absi#NASDAQ">ABSI</a>) gained 7.4% to $6.06.</li>
<li>Hudbay Minerals Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hbm#NYSE">HBM</a>) climbed 7.2% to $8.01 after B of A Securities upgraded the stock from Neutral to Buy.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) rose 7% to $5.06. Roth MKM analyst Joe Reagor initiated coverage on Coeur Mining with a Buy rating and announced a price target of $5.4.</li>
<li>Bilibili Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bili#NASDAQ">BILI</a>) gained 5.6% to $11.70.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvi#NASDAQ">MRVI</a>) gained 5.5% to $8.30.</li>
<li>Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) shares rose 2.3% to $176.93. Goldman Sachs analyst Mark Delaney maintained Tesla with a Neutral and lowered the price target from $190 to $175, while Morgan Stanley analyst Adam Jonas maintained the stock with an Overweight and maintained a $310 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38155367/jim-cramer-was-upset-at-this-hostile-takeover-but-they-fixed-the-situation-stocks-been-a"> Jim Cramer Was Upset At This Hostile Takeover, But &#39;They Fixed The Situation. Stock&#39;s Been A Horse&#39;</a>

U.S. stock futures were lower this morning, with the Dow futures falling by around 100 points on Monday.
Shares of GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) shares rose sharply in today&rsquo;s <a href="https://www.benzinga.com/quote/GDS">pre-market trading</a>.
Hillhouse Capital, Boyu Capital and CDH Investments are reportedly in advanced discussions to invest in the company&rsquo;s data center business outside China, according to Bloomberg.
GDS Holdings shares jumped 17.7% to $7.54 in pre-market trading.
Here are some big stocks recording gains in today&rsquo;s pre-market trading session.
<ul>
<li>Graphite Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grph#NASDAQ">GRPH</a>) climbed 19.4% to $3.75 in pre-market trading. Graphite Bio declared a special dividend in connection with proposed merger with Lenz Therapeutics.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kc#NASDAQ">KC</a>) shares gained 13.7% to $3.06 in pre-market trading. Kingsoft Cloud is expected to report fourth-quarter financial results on March 20, 2024.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) shares rose 9.5% to $6.58 in pre-market trading. Revance recently announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>NuScale Power Corporation(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) gained 9.1% to $5.99 in pre-market trading. NuScale Power is expected to release fourth quarter results on March 14, 2024.</li>
<li>Hesai Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsai#NASDAQ">HSAI</a>) gained 9% to $6.28 in pre-market trading. Hesai Group is expected to report its fourth quarter unaudited financial results on March 11, 2024.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 7.6% to $1,533.99 in pre-market trading amid continued strength in Bitcoin.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 6.7% to $25.06 in pre-market trading amid continued strength in Bitcoin.</li>
<li><a href="https://www.benzinga.com/money/coinbase-alternative/">Coinbase</a> Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) rose 6.4% to $273.15 in pre-market trading amid continued strength in Bitcoin. On Friday, Goldman Sachs upgraded the stock from Sell to Neutral and announced a $282 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37578935/investor-sentiment-falls-following-jobs-data-dow-records-weekly-loss"> Investor Sentiment Falls Following Jobs Data, Dow Records Weekly Loss</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session

Shares of Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) rose sharply during Monday&rsquo;s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>BitFuFu Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fufu#NASDAQ">FUFU</a>) shares jumped 107% to $13.20 amid volatility following the company&#39;s recent business combination with Arisz Acquisition Corp and listing on the Nasdaq.</li>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qnrx#NASDAQ">QNRX</a>) climbed 89% to $5.31 after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) gained 52.8% to $1.5890 after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) climbed 42.7% to $10.11. Phunware is expected to report fourth-quarter results on March 12, 2024.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) gained 39.4% to $1.4650.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares climbed 38.2% to $0.1223 after surging 50% on Friday.</li>
<li>Cardiff Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>) rose 31.6% to $3.83 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) gained 31.3% to $4.94. E.W. Scripps Director Charles L. Barmonde acquired a total of 10,500 shares an average price of $4.28.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsdt#NASDAQ">HSDT</a>) climbed 30% to $5.91. Helius Medical Technologies announced it secured HCPCS codes for portable neuromodulation stimulator mouthpiece and controller.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) gained 27% to $1.14. Kineta recently announced a restructuring and the exploration of strategic alternatives.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 25% to $4.3472.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) gained 24.4% to $12.44.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 22% to $2.44.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) rose 21.7% to $0.6299 after gaining 11% on Friday.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) climbed 21.1% to $33.69 after gaining 3% on Friday.</li>
<li>89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) gained 20.3% to $15.18.</li>
<li>Nektar Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktr#NASDAQ">NKTR</a>) gained 19.4% to $0.9315. Nektar Therapeutics announced a $30 million private placement financing with TCGX.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) shares gained 18.9% to $1,076.45. Super Micro Computer will join the S&amp;P 500 Index, effective March 18, S&amp;P Dow Jones Indices, a division of S&amp;P Global, said in a release.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 17.8% to $1,271.51 amid strength in Bitcoin.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) rose 16.3% to $20.95 after Arkhouse and Brigade Capital increased their offer to acquire Macy&#39;s to $24 per share.</li>
<li>Renovaro Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/renb#NASDAQ">RENB</a>) gained 14.3% to $2.64.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) gained 13.4% to $44.18 after falling over 5% on Friday.</li>
<li>MGE Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgee#NASDAQ">MGEE</a>) rose 12% to $70.75. MGE Energy will replace iRobot in the S&amp;P SmallCap 600.</li>
<li>BGC Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgc#NASDAQ">BGC</a>) gained 11.8% to $7.93. BGC Group is set to join S&amp;P SmallCap 600.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) climbed 11.6% to $7.10.</li>
<li>H&amp;R Block, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrb#NYSE">HRB</a>) gained 8.9% to $52.08.</li>
<li>Aadi Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aadi#NASDAQ">AADI</a>) shares surged 8.8% to $2.0899 after the company announced publication of long-term efficacy and safety data further supporting FYARRO&reg; for the treatment of malignant PEComa.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares rose 7.7% to $1.11. LifeWallet announced a comprehensive settlement with 28 affiliated property and casualty insurers, benefiting LifeWallet&rsquo;s <a href="https://www.benzinga.com/money/best-medicare-advantage-plans/">medicare</a> clients across the U.S.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) climbed 7.5% to $221.11 amid a rise in the price of Bitcoin.</li>
<li>Box, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/box#NYSE">BOX</a>) gained 6.6% to $28.30. Box will replace Forrester Research Inc in the S&amp;P SmallCap 600.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) fell 42.7% to $1.0830 after the company reported pricing of public offering.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 38.7% to $ .3102&nbsp;following a report suggesting the company may file for bankruptcy soon.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) dipped 35% to $0.8598.</li>
<li>BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) fell 23.3% to $0.4449 after reporting interim results from Phase III CardiAMP cell therapy heart failure trial.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) declined 21.8% to $2.00.</li>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) declined 21.7% to $2.4199. Vivani Medical recently announced the pricing of a $15 million registered direct offering of common stock and warrants.</li>
<li>Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) tumbled 19.8% to $0.40. Interactive Strength recently announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) dipped 19.3% to $5.03</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) fell 18.4% to $4.7395 after jumping 35% on Friday.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) fell 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints.</li>
<li>Playtika Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltk#NASDAQ">PLTK</a>) fell 14.8% to $6.44</li>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) declined 14.7% to $0.1399.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) shares dipped 14.3% to $1.98 after jumping over 15% on Friday. J-Long Group recently declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) fell 14.3% to $0.0474. Sunshine Biopharma, last month, announced closing of $10.0 million underwritten public offering.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) fell 13.6% to $3.0650 after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from ineffective oversight, risk assessment and monitoring activities.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.1% to $5.68 after the company announced the termination of its merger agreement with JetBlue.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) fell 11.6% to $2.3050. Sabre announced exchange of $150 million of existing 4.000% exchangeable senior notes due 2025 for exchangeable senior notes due 2026.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) fell 11.6% to $38.49. B of A Securities analyst Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 11.2% to $6.20. Revance announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) dipped 11.3% to $8.67 after the company announced that it was unable to file its annual report due to technical difficulties in assembling the submission for filing. Also, the company said it anticipates it will seek to raise additional capital in 2024.</li>
<li>Caledonia Mining Corporation Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmcl#NASDAQ">CMCL</a>) shares tumbled 9.6% to $9.29 after the company issued a trading update for the year ended Dec. 31, 2023.</li>
<li>Hertz Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htz#NYSE">HTZ</a>) fell 7.2% to $7.26.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) fell 6.9% to $5.38.</li>
</ul>
&nbsp;
Now Read This: <a href="	https://www.benzinga.com/trading-ideas/long-ideas/24/03/37454953/charles-colvard-and-3-other-penny-stocks-insiders-are-buying"> Charles &amp; Colvard And 3 Other Penny Stocks Insiders Are Buying </a>

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
Shares of Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) fell during Monday&rsquo;s session after the company reportedly saw a <a href="https://www.benzinga.com/markets/asia/24/03/37451229/why-tesla-shares-are-down-over-1-premarket-today">decline in February China sales.</a>
Tesla sold 60,365 electric vehicles made in China in February, according to preliminary data released by the China Passenger Car Association, as reported by CnEVPost. The breakdown between exports and domestic sales will be available when the detailed report is released in a week.
Tesla shares fell 5.4% to $191.79 on Monday.
Here are some other big stocks recording losses&nbsp;in today&rsquo;s session.
<ul>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 21.8% to $2.00.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) declined 16.6% to $16.78. Avidity Biosciences announced new long-term AOC 1001 data from the Marina-OLE trial showing reversal of disease progression in Myotonic Dystrophy Type 1 patients across multiple endpoints.</li>
<li>Playtika Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltk#NASDAQ">PLTK</a>) tumbled 14.8% to $6.44</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) declined 13.6% to $3.0650 after the company announced that it identified material weaknesses in its internal controls related to internal loan review, that resulted from ineffective oversight, risk assessment and monitoring activities.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) dipped 12.1% to $5.68 after the company announced the termination of its merger agreement with JetBlue.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) fell 12.1% to $2.70.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) declined 11.6% to $2.3050. Sabre announced exchange of $150 million of existing 4.000% exchangeable senior notes due 2025 for exchangeable senior notes due 2026.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) tumbled 11.6% to $38.49. B of A Securities analyst Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) dipped 11.2% to $6.20. Revance announced pricing of $100 million public offering of 16 million shares of common stock at a price of $6.25 per share.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) shares fell 11.3% to $8.67 after the company announced that it was unable to file its annual report due to technical difficulties in assembling the submission for filing. Also, the company said it anticipates it will seek to raise additional capital in 2024.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 11.1% to $8.14. Cytek Biosciences filed for non-timely 10-K with the U.S. SEC.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) fell 10.8% to $10.04. Sana Biotechnology recently reported a year-over-year increase in quarterly financial results.</li>
<li>ADS-TEC Energy PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adse#NASDAQ">ADSE</a>) fell 10.5% to $9.71.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) declined 10.6% to $30.32.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eypt#NASDAQ">EYPT</a>) fell 9.5% to $25.33. EyePoint Pharmaceuticals announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.</li>
<li>Omeros Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omer#NASDAQ">OMER</a>) fell 9.3% to $4.3350.</li>
<li>iRhythm Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irtc#NASDAQ">IRTC</a>) tumbled 9% to $109.64. iRhythm announced a proposed offering of $450 million of convertible senior notes.</li>
<li>Hertz Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htz#NYSE">HTZ</a>) dipped 7.2% to $7.26.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) declined 6.9% to $5.38.</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell 6.8% to $10.58.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) fell 5.8% to $26.77.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 5.3% to $27.36.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37458044/bitcoin-surpasses-65-000-pepe-emerges-as-top-gainer"> Bitcoin Surpasses $65,000; Pepe Emerges As Top Gainer</a>

ACMR

ADSE

CTKB

EYPT

IRTC

OMER

RIVN

SANA

VSCO

Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday

Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) ("Revance" or the "Company") today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about March 6, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY&#xAE; and the RHA&#xAE; Collection of dermal fillers, support the launch of DAXXIFY&#xAE; into the therapeutics market, as well as for working capital, research and development and general corporate purposes.
Barclays is acting as the sole book-running manager for the proposed offering.

Offerings

Revance Announces Pricing Of $100M Public Offering Of 16M Shares Of Common Stock At A Price Of $6.25/Share

WIIM

Revance Therapeutics shares are trading lower after the company announced a proposed public offering of $100 million of its common stock.

Health Care

Financing

Revance Announces Proposed Public Offering Of $100M Common Stock

Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and raises the price target from $8 to $9.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on Revance Therapeutics, Raises Price Target to $9

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Buy and maintains $12 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target

Revance Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Shares of Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) fell sharply during Thursday&rsquo;s session after the company reported mixed fourth-quarter financial results.
Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company&rsquo;s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million.
Butterfly Network shares dipped 21.7% to $1.1588 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of compounds.</li>
<li>Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares climbed 132.7% to $1.07 as the company agreed to be acquired by CoreRx, Inc.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) gained 55.4% to $1.8802 after surging around 39% on Wednesday.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) climbed 39.7% to $7.78.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 36.4% to $2.1008. Ocean Biomedical announced joint venture partner, Virion Therapeutics to present clinical study data at 2024 APASL Global Liver Meeting.</li>
<li>Inseego Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insg#NASDAQ">INSG</a>) rose 34.5% to $3.00.</li>
<li>Vertex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verx#NASDAQ">VERX</a>) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) rose 29.1% to $2.93 following fourth-quarter results.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) gained 27% to $0.6161. Agrify announced a $3.4 million sales order from New Jersey woman-owned business HarvestWorks Farm.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) climbed 26.5% to $1.05 after the company announced that effective Mar. 1, the US approved adding the company&#39;s kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract.</li>
<li>Tutor Perini Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpc#NYSE">TPC</a>) gained 26% to $11.64 following fourth-quarter results.</li>
<li>Bright Scholar Education Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bedu#NYSE">BEDU</a>) gained 25.3% to $2.3178.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Sterling Check Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ster#NASDAQ">STER</a>) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) gained 24% to $2.00. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Latham Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swim#NASDAQ">SWIM</a>) climbed 22.8% to $3.36.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.6% to $237.82 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose 19.8% to $104.55 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) gained 19.5% to $5.80 after the company reported fourth-quarter financial results.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 17.8% to $45.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) gained 16.7% to $38.52 following quarterly results.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) climbed 16.1% to $13.65.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) rose 15% to $6.91 following strong quarterly results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 14.4% to $14.17 following upbeat quarterly results.</li>
<li>Magnite, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgni#NASDAQ">MGNI</a>) rose 13.8% to $11.93 following strong quarterly results.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indp#NASDAQ">INDP</a>) rose 13.8% to $2.23.</li>
<li>Hayward Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hayw#NASDAQ">HAYW</a>) gained 13.7% to $14.88 following upbeat results.</li>
<li>Hormel Foods Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrl#NYSE">HRL</a>) rose 12.8% to $34.81 after the company reported better-than-expected first-quarter earnings and reaffirmed FY24 outlook.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares rose 9.2% to $0.7750. Nxu said it fully regained compliance with Nasdaq&#39;s continued listing requirements.</li>
<li>NFT Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mi#NYSE">MI</a>) shares jumped 7.9% to $0.2374.</li>
<li>Sprinklr, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cxm#NYSE">CXM</a>) gained 7.9% to $13.56. Sprinklr will replace Veradigm in S&amp;P SmallCap 600 effective prior to opening of trading on March 4, 2024.</li>
<li>Papa John&#39;s International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pzza#NASDAQ">PZZA</a>) climbed 6.8% to $74.89 following strong quarterly earnings.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>J-Long Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jl#NYSE">JL</a>) fell 46.3% to $6.86. J-Long Group declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Golden Minerals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aumn#NYSE">AUMN</a>) dipped 40.4% to $0.3163. Golden Minerals announced that it has elected to stop operations at its Velarde&ntilde;a Properties, located in Durango State, Mexico.</li>
<li>LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares declined 40% to $1.43 following fourth-quarter financial results.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 40% to $2.99.</li>
<li>Endava plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dava#NYSE">DAVA</a>) fell 40% to $38.31 following second-quarter earnings.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 39.7% to $1.3801 as the company announced intention to explore strategic alternatives.</li>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) fell 39% to $9.23 after the company&#39;s Phase 3 trial of once-weekly subcutaneous apraglutide did not meet two out of four key secondary endpoints.</li>
<li>Xometry, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xmtr#NASDAQ">XMTR</a>) fell 37.4% to $18.84 after the company reported fiscal fourth-quarter results and issued first-quarter guidance below estimates and disclosed a CFO transition.</li>
<li>Grifols, S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NYSE">GRFS</a>) fell 36.7% to $5.91.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares declined 33.7% to $19.05. Chemours Company named Denise Dignam as the interim CEO and Matt Abbott as the interim CFO. The company also issued preliminary 2023 results.</li>
<li>Bakkt Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkkt#NASDAQ">BKKT</a>) fell 33.4% to $0.6792 after the company announced two securities purchase agreements.</li>
<li>CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) dipped 30% to $1.2950 after the company reported financial fourth-quarter results below estimates.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 25.2% to $11.43.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) dropped 22% to $19.34.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) fell 21.8% to $7.71.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 20.2% to $0.1621. BYND Cannasoft is entering into production agreements for its EZ-G Device.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares tumbled 20.1% to $183.81. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares declined 19.9% to $25.12 after the company reported mixed fourth-quarter financial results.</li>
<li>Castle Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cstl#NASDAQ">CSTL</a>) fell 18.7% to $19.83 following fourth-quarter financial results.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) fell 18.2% to $1.3750.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) shares fell 18.1% to $47.50 after posting a loss for the fourth quarter.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) fell 17.9% to $3.1350 after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>uniQure N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qure#NASDAQ">QURE</a>) fell 16.7% to $5.57. Goldman Sachs analyst Salveen Richter downgraded uniQure from Buy to Neutral and lowered the price target from $63 to $8.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) fell 16.7% to $1.09 following quarterly results.</li>
<li>DoubleVerify Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dv#NYSE">DV</a>) declined 16.6% to $32.71 after the company reported fourth quarter financial results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) shares dipped 16.3% to $12.89 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) shares fell 16% to $1.7897 after announcing a proposed public offering of common shares and pre-funded warrants.</li>
<li>COMPASS Pathways plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmps#NASDAQ">CMPS</a>) fell 16% to $10.40 following a wider-than-expected quarterly loss.</li>
<li>FIGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/figs#NYSE">FIGS</a>) shares fell 15.4% to $5.10 after the company reported mixed quarterly financial results.</li>
<li>The Lion Electric Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lev#NYSE">LEV</a>) dipped 12.6% to $1.46 following fourth quarter financial results.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 12.2% to $7.67 following fourth quarter financial results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) shares fell 11.1% to $4.4350 following quarterly results.</li>
<li>Titan International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twi#NYSE">TWI</a>) fell 10% to $12.73 following weak sales.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) shares declined 7.2% to $10.45 after the company reported mixed fourth quarter financial results.</li>
<li>Array Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arry#NASDAQ">ARRY</a>) fell 5.8% to $13.27.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbwi#NASDAQ">BBWI</a>) fell 5.2% to $45.80 after the company reported fourth-quarter earnings and issued worse-than-expected FY24 outlook. It also authorized $500 million stock buyback.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) shares fell 3.7% to $108.03 after the company reported financial fourth-quarter results below estimates.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37390717/nvidia-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday"> NVIDIA To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday</a>

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CSTL

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OKTA

ORIC

PSTG

PZZA

QURE

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares increased by 28.91% to $1.07. The company's market cap stands at $53.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares fell 42.5% to $1.3 during Thursday's regular session. The market value of their outstanding shares is at $13.5 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 39.89% to $9.09. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 27.63% to $6.76. The company's market cap stands at $4.5 billion. </li>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) shares fell 24.35% to $1.74. The market value of their outstanding shares is at $1.9 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares fell 22.37% to $19.25. The company's market cap stands at $1.6 billion. </li>
<li>Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) stock fell 20.85% to $19.3. The market value of their outstanding shares is at $519.5 million. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPE

Envoy Medical, Inc. - Class A Common Stock

COCH

TIVC

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.
Shares of Hormel Foods Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrl#NYSE">HRL</a>) rose sharply during Thursday&rsquo;s session after the company reported better-than-expected first-quarter <a href="https://www.benzinga.com/news/earnings/24/02/37392276/why-hormel-foods-shares-are-rising-today">earnings and reaffirmed FY24 outlook</a>.
The company reported first-quarter adjusted earnings per share of 41 cents, beating the analyst consensus of 34 cents. Quarterly revenues of $2.997 billion, beating the analyst consensus of $2.917 billion.
Hormel Foods shares climbed 12.6% to $34.72 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Vertex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verx#NASDAQ">VERX</a>) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance.</li>
<li>Tutor Perini Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpc#NYSE">TPC</a>) gained 26% to $11.64 following fourth-quarter results.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Sterling Check Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ster#NASDAQ">STER</a>) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.6% to $237.82 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose 19.8% to $104.55 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) gained 19.5% to $5.80 after the company reported fourth-quarter financial results.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 17.8% to $45.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) gained 16.7% to $38.52 following quarterly results.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) climbed 16.1% to $13.65.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) rose 15% to $6.91 following strong quarterly results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 14.4% to $14.17 following upbeat quarterly results.</li>
<li>Magnite, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgni#NASDAQ">MGNI</a>) rose 13.8% to $11.93 following strong quarterly results.</li>
<li>Hayward Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hayw#NASDAQ">HAYW</a>) gained 13.7% to $14.88 following upbeat results.</li>
<li>Sprinklr, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cxm#NYSE">CXM</a>) gained 7.9% to $13.56. Sprinklr will replace Veradigm in S&amp;P SmallCap 600 effective prior to opening of trading on March 4, 2024.</li>
<li>Papa John&#39;s International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pzza#NASDAQ">PZZA</a>) climbed 6.8% to $74.89 following strong quarterly earnings.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37389900/top-3-real-estate-stocks-which-could-rescue-your-portfolio-this-month"> Top 3 Real Estate Stocks Which Could Rescue Your Portfolio This Month</a>

Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday

Piper Sandler analyst David Amsellem maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Overweight and lowers the price target from $42 to $20.

Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $20

Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Buy and lowers the price target from $20 to $18.

Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $18

2024 Guidance and Financial Outlook
•Product revenue guidance: Revance expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million. Product revenue guidance for 2024 reflects the following assumptions:
◦RHA Collection DAXXIFY Aesthetic market share growth through deeper and broader account penetration.
◦DAXXIFY cervical dystonia launch expected mid-year 2024 and related modest revenue contribution.
•Operating expense guidance: Revance expects 2024 GAAP operating expenses to be between $460 million to $490 million and non-GAAP operating expenses, which exclude goodwill and intangible asset impairment, costs of revenues (exclusive of amortization), stock-based compensation, depreciation and amortization and restructuring charges to be between $290 million to $310 million. The midpoints of the GAAP and non-GAAP operating expense guidance ranges represent a corresponding 14% and 6% reduction from the company's 2023 operating expenses. The reduction is driven primarily by the exit of the company's OPUL payments business, in addition to the streamlining of the organization and improved operating efficiencies. Revance expects non-GAAP selling, general and administrative (SG&amp;A) expenses to be between $240 million to $255 million.
•Financial outlook: With cash, cash equivalents, and short-term investments of $253.9 million as of December 31, 2023, and anticipated revenues and expenditures, management projects that the company will be funded to cash flow break-even and reach positive Adjusted EBITDA in 2025.
Longer-term, the company reaffirms its blockbuster potential in U.S. aesthetics supported by its innovative product portfolio including DAXXIFY and the RHA Collection. The company expects to increase revenue growth through deeper and broader account penetration of DAXXIFY and RHA and the introduction of new RHA indications and products.
 Further, the company believes meaningful upside can be achieved with the expansion of DAXXIFY into therapeutics and internationally, as well as the company's strategic partnerships with Fosun and Viatris – representing at least $5.0 billion in potential future growth opportunities1.

Guidance

Revance Expects 2024 Total Product Revenue, Which Includes Sales Of DAXXIFY And The RHA Collection, To Be At Least $280M

Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 65.93 percent increase over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $69.80 million which beat the analyst consensus estimate of $62.63 million by 11.45 percent. This is a 39.82 percent increase over sales of $49.92 million the same period last year.

Earnings

Revance Therapeutics Q4 EPS $(0.62) Beats $(0.72) Estimate, Sales $69.80M Beat $62.63M Estimate